Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666

Article  PubMed  Google Scholar 

Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ (2013) Triptan nonresponders: do they exist and who are they? Cephalalgia 33(11):891–896

Article  PubMed  Google Scholar 

Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21(1):41

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN et al (2020) Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia 40(7):639–649

Article  PubMed  PubMed Central  Google Scholar 

Wilcha RJ, Goadsby PJ (2024) Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study. Cephalalgia 44(9):3331024241278911

Article  PubMed  Google Scholar 

Dodick DW (2005) Triptan nonresponder studies: implications for clinical practice. Headache 45(2):156–162

Article  PubMed  Google Scholar 

Terrazzino S, Viana M, Floriddia E, Monaco F, Mittino D, Sances G et al (2010) The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol 641(2–3):82–87

Article  CAS  PubMed  Google Scholar 

Christensen AF, Esserlind AL, Werge T, Stefánsson H, Stefánsson K, Olesen J (2016) The influence of genetic constitution on migraine drug responses. Cephalalgia 36(7):624–639

Article  PubMed  Google Scholar 

Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 11(5):431–435

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puledda F, Younis S, Huessler EM, Haghdoost F, Lisicki M, Goadsby PJ et al (2023) Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia 43(3):3331024231151419

Article  PubMed  Google Scholar 

Lo Castro F, Guerzoni S, Pellesi L (2021) Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug Healthc Patient Saf 13:233–240

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong P, Tan T, Liu Y, Xiao J (2020) Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav 10(8):e01701

Article  PubMed  PubMed Central  Google Scholar 

Rissardo JP, Caprara ALF (2022) Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci. 12(12):1612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023): The Cochrane Collaboration; 2023 [cited 2023 Dec 14]. Available from: www.training.cochrane.org/handbook.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 372:n71

PubMed  Google Scholar 

Cochrane Effective Practice and Organisation of Care (EPOC). (2020). Good practice data extraction form. Oxford: Cochrane Effective Practice and Organisation of Care (EPOC). Retrieved October 15, 2023, from https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/good_practice_data_extraction_form.doc

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898

Article  PubMed  Google Scholar 

Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M et al (2020) CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17(4):e1003082

Article  PubMed  PubMed Central  Google Scholar 

Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA et al (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630

Article  PubMed  Google Scholar 

Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):405–413

Article  PubMed  Google Scholar 

Kitamura S, Imai N, Tanji Y, Ozeki A, Komori M (2023) Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study. J Pain Res 16:1725–1738

Article  CAS  PubMed  PubMed Central  Google Scholar 

Komori M, Ozeki A, Tanji Y, Kamiki E, Krege JH, Li LQ et al (2024) Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial. J Headache Pain 25(1):43

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114–125

Article  PubMed  Google Scholar 

Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE et al (2022) Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain 23(1):50

Article  CAS  PubMed  PubMed Central  Google Scholar 

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737–745

Article  CAS  PubMed  Google Scholar 

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894–1904

Article  PubMed  PubMed Central  Google Scholar 

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB (2018) Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 91(24):e2222–e2232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA 322(19):1887–1898

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M et al (2019) Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain 20(1):84

Article  PubMed  PubMed Central  Google Scholar 

Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M (2021) Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61(5):755–765

Article  PubMed  PubMed Central